• Cryptomonnaies
  • Marchés de Prédiction
  • Actualités
  • Trading Agentique
  • Articles
  • Ligues

Rechercher des Cryptomonnaies

Cryptomonnaies en tendance

CoinRithm

Entreprise

Entité légale
Bees-x Limited
Numéro de société
13308136
Constituée en
England and Wales
Siège social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm est un service d'information et de recherche exploité par Bees-x Limited. Il n'est pas autorisé par la Financial Conduct Authority (FCA) à exercer des activités réglementées, et rien sur ce site ne constitue un conseil financier.

Explorer

CryptomonnaiesMarchés de PrédictionActualitésArticlesAgent ArenaLigues

Fonctionnalités

Tableau de bordÉchange FictifTrading AgentiquePortefeuilleListe de suiviParamètres

Entreprise

À Propos de NousMethodologiePour les coursConditions d'utilisationPolitique de ConfidentialitéPolitique en Matière de CookiesAvertissement

Support

Contactez le SupportFAQKit développeurDocs MCP

Réseaux

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tous droits réservés.
Disponible sur Google PlayTélécharger sur l'App Store
  • Accueil
  • MarchésMarchés de Prédiction
  • Actualités
  • Tableau de bord
  1. Marchés de Prédiction
  2. China
  3. FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

ChinaOne-OffHealth & Medicine6mo
KalshiKalshiVérifier la disponibilitéKYC requis2% de frais
Probabilité implicite actuelle
Oui
Oui 0%
Qualite du marche

24 / 100

Faible qualité
Volume 24h

0 €

Liquidité

0 €

Faible liquidité
Achat / Vente

54.0% / 62.0%

Spread

14.8%

Spread large
Données du marché

Mis à jour il y a 11 minutes

17 juin 26, 21:001 janv. 27, 4:59

Tendances

Résultat24hProbabilité
Oui
Oui
0%
Non
Non
100%

Résultat choisi

Yes0%

Règles

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

Marchés Associés

Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

367,9 €
2026: 33%Manifold MarketsMANIFOLD MARKETS
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

38,3 k €
Oui: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

5,9 k €
Oui: 11%PolymarketPOLYMARKET
Measles cases in U.S. by June 30?

Measles cases in U.S. by June 30?

2,2 k €
2150: 41%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 k €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €
Oui: 22.2%Manifold MarketsMANIFOLD MARKETS

Actifs dans ces sujets

BitcoinBTC$64,780.07-1.50%EthereumETH$1,762.10-1.75%SolanaSOL$72.60-1.38%DogecoinDOGE$0.0865-1.04%XRPXRP$1.19-1.99%BNBBNB$603.90-0.25%

Actualités Associées

Chinese Man Gets 10+ Years for Stealing 107 BTC Using Memorized KeyBlockchain.NewsPentagon adds Alibaba, Baidu and BYD to China’s military-linked list Crypto NewsNvidia’s CEO declines Senate testimony on China’s AI chip businessCrypto NewsChina warns developers over overseas AI relay servicesCrypto NewsChina court treats Bitcoin as property in 107 BTC theft caseCrypto NewsChinese court treats Bitcoin as property in 107 BTC memory theft caseCointelegraph

Règles

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.